Prices for Drugs Prescribed to Seniors: Department of Veterans Affairs (VA) Versus Plans from Top Part D Insurers, November 2006

| Drug <br> Name | Lowest VA <br> Price Per Year | Lowest Part D <br> Price Per Year | Highest Part D <br> Price Per Year |
| :--- | :---: | :---: | :---: |
| Celebrex (200mg) | $\$ 632.09$ | $\$ 946.44$ | $\$ 1,107.36$ |
| Fosamax $(70 \mathrm{mg})$ | $\$ 250.32$ | $\$ 763.56$ | $\$ 902.64$ |
| Lipitor $(10 \mathrm{mg})$ | $\$ 520.49$ | $\$ 785.40$ | $\$ 946.92$ |
| Nexium $(40 \mathrm{mg})$ | $\$ 848.45$ | $\$ 1,433.16$ | $\$ 1,652.04$ |
| Protonix $(40 \mathrm{mg})$ | $\$ 214.52$ | $\$ 1,148.40$ | $\$ 1,333.20$ |
| Zocor $(20 \mathrm{mg})$ | $\$ 127.44$ | $\$ 1,485.96$ | $\$ 1,693.92$ |

## 2005 Financials for Top Seven U.S. Pharmaceutical Companies

| Company | Revenue (Net Sales)* | Marketing, <br> Advertising, and Administration* |  | Research and Development* |  | Profit (Net Income)* |  | Marketing, <br> Advertising, and Administration Spending as a Multiple of R\&D Spending |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Dollars | Percent | Dollars | Percent | Dollars | Percent |  |
| Pfizer | \$51,298 | \$16,997 | 33.1\% | \$7,442 | 14.5\% | \$8,085 | 15.8\% | 2.3 |
| Johnson and Johnson | \$50,514 | \$16,877 | 33.4\% | \$6,312 | 12.5\% | \$10,411 | 20.6\% | 2.7 |
| Abbott Laboratories | \$22,338 | \$5,496 | 24.6\% | \$1,838 | 8.2\% | \$3,372 | 15.1\% | 3.0 |
| Merck | \$22,012 | \$7,156 | 32.5\% | \$3,848 | 17.5\% | \$4,631 | 21.0\% | 1.9 |
| Bristol-Myers Squibb | \$19,380 | \$6,427 | 33.2\% | \$2,500 | 12.9\% | \$2,388 | 12.3\% | 2.6 |
| Wyeth | \$18,756 | \$6,1 18 | 32.6\% | \$2,749 | 14.7\% | \$3,656 | 19.5\% | 2.2 |
| Eli Lilly | \$14,645 | \$4,497 | 30.7\% | \$3,026 | 20.7\% | \$1,980 | 13.5\% | 1.5 |
| Total | \$198,943 | \$63,568 |  | \$27,715 |  | \$34,523 |  |  |
| Average |  |  | 32.0\% |  | 13.9\% |  | 17.4\% | 2.3 |

* Dollars in millions

